분야
doc1.1 Scale of Pharmaceutical Market
1.2 Export
1.3 Import
1.4 India’s Advantage
1.5 Key Trends & Drivers
Chapter 2. Price controlling policy
2.1 India’s Price Mechanism for Pharmaceutical products
2.2 The history of revising DPCO
2.3 Comparing results between controlling and decontrolling policy
2.4 India’s pharmaceutical Industry in consumer side
Chapter 3. India's pharmaceutical patent system and TRIPS regime
3.1 Pharmaceutical industry of INDIA - strong generic industry
3.2 Patent Act, 1970 of INDIA
3.3 Access to WTO
3.4 What is TRIPS?
3.5 Process of adopting TRIPS agreement
3.6 Amendments of the Indian Patents Act under the TRIPS Regime
3.7 New trend of pharmaceutical industry of INDIA
Chapter 4. Conclusion
Reference
1.1 Scale of Pharmaceutical Market
1.1.1 Domestic pharmaceutical market
India is among the fastest growing pharmaceutical markets in the world. The domestic pharmaceutical market recorded sales of US$ 7.3 billion in 2006 with a growth of 17.5 per cent over the previous year.
1.1.2 Pharmaceutical Industry
The Indian pharmaceutical industry was estimated to be around US$ 13.2 billion in 2006-07. Of this, domestic consumption of pharmaceuticals accounted for nearly 57 per cent while the rest 43 per cent was constituted by exports.
1.1.3 Expectation
In the long run, the market is expected to maintain a healthy growth rate of 12-13 per cent. It is expected to cross US$ 10 billion mark by 2010 and would reach US$ 12 to 13 billion approximately, by 2012.
1.2 Exports
1.2.1Formulation exports would lead the way
With US$ 5.2 billion of estimated revenues in 2005-06, exports have become the mainstay of the Indian pharmaceutical industry. Presently, the share of bulk drugs exceeds that of formulations in the total pharmaceutical exports.
Overall pharmaceutical exports are estimated to increase at a CAGR of 30-32 per cent and reach US$ 18.3 billion in 2010-11. Moving at a healthy CAGR of 30-35 per cent, formulation exports are estimated to reach US$ 9.6 billion by 2010-11 and would surpass bulk drugs which are estimated to reach US$ 8.7 billion at a CAGR of 25 per cent in the same period.
2. NIPER(National Institute of Pharmaceutical Ecudaion&Research,”Impact of TRIPs on Pharmaceutical Prices”, APRIL 2006
3. Sakthivel Selvaraj&Takemi Fellow, “How Effective is India’s Drug Price Control Regime?”, Harvard School of Public Health Boston, MA USA, JULY 2007.
4. AIDIAN(All India Drug Action Network),”Medicine Pricec and Affordability-A Policy Brief On Drug Pricing”,March 2009
5. http://nppaindia.nic.in (NPPA)
6. 김희상(주 인도대사관 1등 서기관), “인도의 의약품 특허 제도와 TRIPS 규범”,April 2007.
7. Uwe Perlitx Detutsche Bank Research Frankfurt am Main Germany, “India’s
Pharmaceutical industry on course for globalization”, April 2008.
8. BISWAJIT DAHR, “Post-2005 TRIPS scenario in patent protection in the pharmaceutical sector : The case of the generic Pharmaceutical Industry In India”. Novemver 2006”
9. 머니투데이, “노바티스, R&D 투자 인도에서 중국으로”,2007.8.22.
- 오늘 본 자료가 없습니다.
- 사회복지조사론토론- A 노인 요양원에서 생활하는 노인 클라이언트들의 욕구를 파악하기 위하여 조사를 진행하고 있다 면접조사가 바람직할지 또는 설문조사 바람직할지 토론하시오
- 아동발달과 연계한 아동미술의 필요성을 설명하고, 아동발달 지원을 위해 예비보육교사로서 갖추어야 할 아동미술 지도 역량을 기술하시오
- 사회복지정책의 순기능과 역기능을 각각 설명하고, 현재 시행중인 사회복지(정책)제도를 선택하여 예상되는 순기능과 역기능을 설명해주세요
- 사회복지 현장에서 일어날수 있는 윤리적 딜레마 상황을 알아보고 해당 상황에 대해 학습자 본인의 개인적 가치, 사회복지사로서의 전문적가치, 사회적가치는 무엇인지 기술하시오
- 보육교사의 역할과 자질에 대해 설명하시오
해당 정보 및 게시물의 저작권과 기타 법적 책임은 자료 등록자에게 있습니다. 위 정보 및 게시물 내용의 불법적 이용,무단 전재·배포는 금지되어 있습니다. 저작권침해, 명예훼손 등 분쟁요소 발견 시 고객센터에 신고해 주시기 바랍니다.
